475272-62-9 Usage
General Description
2-Pyridinecarboxylic acid, 6-methoxy-5-nitro-(9CI) is a chemical compound with the molecular formula C8H7NO5. It is a derivative of pyridinecarboxylic acid with a methoxy group and a nitro group attached to the 6th and 5th positions, respectively. 2-Pyridinecarboxylicacid,6-methoxy-5-nitro-(9CI) is commonly used in the pharmaceutical industry for its potential medicinal properties, such as its anti-inflammatory and anti-bacterial effects. Its structural and functional properties make it a valuable component in drug discovery and development processes. However, further research is necessary to fully understand and harness its potential therapeutic applications.
Check Digit Verification of cas no
The CAS Registry Mumber 475272-62-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,5,2,7 and 2 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 475272-62:
(8*4)+(7*7)+(6*5)+(5*2)+(4*7)+(3*2)+(2*6)+(1*2)=169
169 % 10 = 9
So 475272-62-9 is a valid CAS Registry Number.
475272-62-9Relevant articles and documents
2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY
-
Page/Page column 104-105, (2019/11/12)
A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of cancers, inflammation, autoimmune diseases and graft-versus host diseases (e.g. in transplantation patients). A pharmaceutical composition comprising the compound or its salt and a method for preparing the compound.
Proteomimetic compounds and methods
-
, (2008/06/13)
The present invention relates to compounds and pharmaceutical compositions which are proteomimetic and to methods for inhibiting the interaction of an alpha-helical protein with another protein or binding site. Methods for treating diseases or conditions which are modulated through interactions between alpha helical proteins and their binding sites are other aspects of the invention.
